119-HR-8115 Journalist Public Summary

Headline Summary

A bill to boost brain‑health research and care for veterans by expanding the VA’s precision medicine program, creating a VA–DoD data‑sharing partnership, requiring targeted studies on low‑level blast exposure, and funding the effort at $5 million per year through 2030.

What It Does

This bill, the Precision Brain Health Research Act of 2026 (H.R. 8115), updates an existing VA precision‑medicine initiative to more directly tackle brain and mental health issues tied to military service. It adds repetitive low‑level blast exposure and dementia to the program’s focus; orders the VA and the Department of Defense to build a shared, open-platform data hub; and lays out specific research the VA must run—ranging from “big‑data” reviews of what treatments are helping veterans today to large, real‑world studies and a translational study of growth‑hormone therapy. Independent review by the National Academies is built in, and the VA must send regular progress reports to Congress.

• Expands scope: explicitly adds repetitive low‑level blast exposure and dementia to the VA initiative.
• Creates a VA–DoD data‑sharing partnership housed on an open platform, pulling in relevant data from the Armed Forces, U.S. Special Operations Command, and the LIMBIC‑CENC consortium.
• Mandates research: a big‑data assessment; at least two large implementation studies; at least four quality‑improvement studies; and a translational study of growth‑hormone replacement therapy for likely low‑level blast injuries.
• Requires independent validation of brain and mental‑health biomarkers by the National Academies and regular reports to Congress.
• Authorizes funding of $5,000,000 per year for FY2025–FY2030.

Key Numbers and Deadlines

Who’s For It

• Sponsor: Rep. Mariannette Miller‑Meeks (R‑IA).
• Veterans’ health advocates and some defense‑health researchers are likely to support stronger VA–DoD data sharing and faster translation of proven treatments into routine care, especially for blast‑related injuries.
• Lawmakers focused on Veterans’ Affairs and Armed Services may back the bill’s oversight pieces (National Academies review and recurring reports) that promise clearer accountability.

Who’s Against It

• Privacy and data‑security advocates could raise concerns about an “open platform” housing sensitive VA–DoD health data and how consent, access controls, and de‑identification are handled.
• Fiscal hawks may question whether $5M/year is sufficient impact for the cost—or argue the work duplicates existing VA or DoD efforts.
• Clinical skeptics may object to naming growth‑hormone therapy in statute before stronger evidence on benefits and risks in this population.
• Process critics could worry about scope creep or unclear definitions (for example, who qualifies as having “likely” low‑level repetitive blast injuries).

What’s Next

Status as of March 26–27, 2026: Introduced in the House on March 26, 2026 and referred to the Committees on Veterans’ Affairs and Armed Services. Next steps typically include committee hearings and markups, potential cost estimates, and a House floor vote; if it passes, the bill would move to the Senate and, if approved there, to the President.